187 related articles for article (PubMed ID: 10760769)
1. Improved prediction of calcitonin normalization in medullary thyroid carcinoma patients by quantitative lymph node analysis.
Machens A; Gimm O; Ukkat J; Hinze R; Schneyer U; Dralle H
Cancer; 2000 Apr; 88(8):1909-15. PubMed ID: 10760769
[TBL] [Abstract][Full Text] [Related]
2. Impact of modified radical neck dissection on biochemical cure in medullary thyroid carcinomas.
Weber T; Schilling T; Frank-Raue K; Colombo-Benkmann M; Hinz U; Ziegler R; Klar E
Surgery; 2001 Dec; 130(6):1044-9. PubMed ID: 11742336
[TBL] [Abstract][Full Text] [Related]
3. Prediction of mediastinal lymph node metastasis in medullary thyroid carcinoma.
Machens A; Holzhausen HJ; Dralle H
Br J Surg; 2004 Jun; 91(6):709-12. PubMed ID: 15164439
[TBL] [Abstract][Full Text] [Related]
4. [Lymph node involvement and prognosis in medullary cancers of the thyroid gland].
Mathonnet M; Cubertafond P; Teissier MP; Boutros-Toni F; Gainant A
Chirurgie; 1994-1995; 120(12):117-22. PubMed ID: 8746014
[TBL] [Abstract][Full Text] [Related]
5. Results of surgical treatment of sporadic medullary thyroid carcinoma following routine measurement of serum calcitonin.
Mirallié E; Iacobone M; Sebag F; Henry JF
Eur J Surg Oncol; 2004 Sep; 30(7):790-5. PubMed ID: 15296996
[TBL] [Abstract][Full Text] [Related]
6. Can sporadic medullary thyroid carcinoma be biochemically predicted? Prospective analysis of 66 operated patients with elevated serum calcitonin levels.
Iacobone M; Niccoli-Sire P; Sebag F; De Micco C; Henry JF
World J Surg; 2002 Aug; 26(8):886-90. PubMed ID: 12016469
[TBL] [Abstract][Full Text] [Related]
7. Changes in risk factors and Tumor Node Metastasis stage of sporadic medullary thyroid carcinoma over 41 years, before and after the routine measurements of serum calcitonin.
Karga H; Giagourta I; Papaioannou G; Doumouchtsis K; Polymeris A; Thanou S; Papamichael K; Zerva C
Metabolism; 2011 May; 60(5):604-8. PubMed ID: 20667564
[TBL] [Abstract][Full Text] [Related]
8. Skip metastases in thyroid cancer leaping the central lymph node compartment.
Machens A; Holzhausen HJ; Dralle H
Arch Surg; 2004 Jan; 139(1):43-5. PubMed ID: 14718274
[TBL] [Abstract][Full Text] [Related]
9. [The concept of "microsurgical" technique in medullary thyroid carcinoma].
Mann B; Buhr HJ; Faulhaber J
Langenbecks Arch Chir Suppl Kongressbd; 1998; 115():720-3. PubMed ID: 9931710
[TBL] [Abstract][Full Text] [Related]
10. Prognostic value of lymph node yield and metastatic lymph node ratio in medullary thyroid carcinoma.
Leggett MD; Chen SL; Schneider PD; Martinez SR
Ann Surg Oncol; 2008 Sep; 15(9):2493-9. PubMed ID: 18594930
[TBL] [Abstract][Full Text] [Related]
11. Individualization of lymph node dissection in RET (rearranged during transfection) carriers at risk for medullary thyroid cancer: value of pretherapeutic calcitonin levels.
Machens A; Lorenz K; Dralle H
Ann Surg; 2009 Aug; 250(2):305-10. PubMed ID: 19638924
[TBL] [Abstract][Full Text] [Related]
12. Enhancement of lymph node metastasis and distant metastasis of thyroid carcinoma.
Machens A; Holzhausen HJ; Lautenschläger C; Thanh PN; Dralle H
Cancer; 2003 Aug; 98(4):712-9. PubMed ID: 12910514
[TBL] [Abstract][Full Text] [Related]
13. Prediction of lateral lymph node metastases in medullary thyroid cancer.
Machens A; Hauptmann S; Dralle H
Br J Surg; 2008 May; 95(5):586-91. PubMed ID: 18300267
[TBL] [Abstract][Full Text] [Related]
14. Rationale for central and bilateral lymph node dissection in sporadic and hereditary medullary thyroid cancer.
Scollo C; Baudin E; Travagli JP; Caillou B; Bellon N; Leboulleux S; Schlumberger M
J Clin Endocrinol Metab; 2003 May; 88(5):2070-5. PubMed ID: 12727956
[TBL] [Abstract][Full Text] [Related]
15. Medullary thyroid microcarcinoma recommendations for treatment - a single-center experience.
Scheuba C; Kaserer K; Bieglmayer C; Asari R; Riss P; Drosten R; Niederle B
Surgery; 2007 Dec; 142(6):1003-10; discussion 1010.e1-3. PubMed ID: 18063088
[TBL] [Abstract][Full Text] [Related]
16. Persistent hypercalcitoninemia in patients with medullary thyroid cancer: a therapeutic approach based on selective venous sampling for calcitonin.
Medina-Franco H; Herrera MF; López G; Tielve-Campillo M; Sierra M; Lozano-Salazar RR; González O
Rev Invest Clin; 2001; 53(3):212-7. PubMed ID: 11496707
[TBL] [Abstract][Full Text] [Related]
17. Neck management in medullary thyroid carcinoma.
Oskam IM; Hoebers F; Balm AJ; van Coevorden F; Bais EM; Hart AM; van den Brekel MW
Eur J Surg Oncol; 2008 Jan; 34(1):71-6. PubMed ID: 17555910
[TBL] [Abstract][Full Text] [Related]
18. Radioactive iodine treatment in medullary thyroid carcinoma.
Faik Erdogan M; Gursoy A; Erdogan G; Kamel N
Nucl Med Commun; 2006 Apr; 27(4):359-62. PubMed ID: 16531922
[TBL] [Abstract][Full Text] [Related]
19. Biomarker-based risk stratification for previously untreated medullary thyroid cancer.
Machens A; Dralle H
J Clin Endocrinol Metab; 2010 Jun; 95(6):2655-63. PubMed ID: 20339026
[TBL] [Abstract][Full Text] [Related]
20. Natural history, diagnosis, treatment and outcome of medullary thyroid cancer: 37 years experience on 157 patients.
Pelizzo MR; Boschin IM; Bernante P; Toniato A; Piotto A; Pagetta C; Nibale O; Rampin L; Muzzio PC; Rubello D
Eur J Surg Oncol; 2007 May; 33(4):493-7. PubMed ID: 17125960
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
